Is There a Role of Radiotherapy in the Management of Pancreatic Neuroendocrine Tumors (PNET)?

  • Muhammad Wasif Saif Columbia University College of Physicians and Surgeons. New York, NY, USA
  • John Ng Columbia University College of Physicians and Surgeons. New York, NY, USA
  • Bryan Chang Yale School of Medicine. New Haven, CT, USA
  • Suzanne Russo Mitchell Cancer Institute, University of South Alabama. Mobile, AL, USA
DOI: https://doi.org/10.6092/1590-8577/690
Keywords: Chemoradiotherapy, Neuroendocrine Tumors, Pancreas

Abstract

Pancreatic neuroendocrine tumors (PNET) represent a heterogeneous group of tumors with varying tumor biology and prognosis. Advanced PNETs remain a difficult therapeutic challenge because of their high malignant potential and their resistance to conventional chemotherapy although there have been recent developments with promising results with the use of novel agents for the treatment of this disease. Combined modality chemoradiation is not widely used in the management of locally advanced pancreatic endocrine tumors. We discuss Abstract #335 from 2012 ASCO GI Cancers Symposium and share our experience to discuss efficacy and toxicity of concurrent capecitabine or infusional 5-fluorouracil and radiotherapy in patients with resected, locally advanced and metastatic PNET. Prospective studies to investigate the role of radiation and chemoradiation are warranted.

Downloads

Download data is not yet available.

Author Biography

Suzanne Russo, Mitchell Cancer Institute, University of South Alabama. Mobile, AL, USA

Philip Rubin Professor of Interdisciplinary Oncology

Department of Radiation Oncology

References

Oberg K. Pancreatic endocrine tumors. Semin Oncol 2010;37:594-618 [PMID 21167379]

Ehehalt F, Saeger HD, Schmidt CM, et al. Neuroendocrine tumors of the pancreas. Oncologist 2009;14:456-467 [PMID 19411317]

Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:514-23 [PMID 21306238]

Raymond E, Dahan L, Raoul J-L, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:501-13 [PMID 21306237]

Oberstein PE, Saif MW. Safety and efficacy of everolimus in adult patients with neuroendocrine tumors. Clin Med Insights Oncol. 2012; 6:41-51 [PMID 22253554]

Jensen RT, Delle Fave G. Promising advances in the treatment of malignant pancreatic endocrine tumors. N Engl J Med 2011;364:564-565 [PMID 21306243]

Bertram W. Maidment, Trevor Ellison, Joseph M. Herman, Navesh K Sharma, Dan Laheru, William Regine, et al. Radiation in the management of pancreatic neuroendocrine tumors. J Clin Oncol 30, 2012 (suppl 4; abstr 335).

Strosberg J, Hoffe S, Gardner N, et al. Effective treatment of locally advanced endocrine tumors of the pancreas with chemoradiotherapy. Neuroendocrinology 2007;85:216-220 [PMID 17541257]

Strimpakos AS, Syrigos KN, Saif MW. Pancreatic neuroendocrine tumors: role of novel agents. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. JOP 2011;12:117-119 [PMID 21386634]

Dawson LA, Jaffray DA. Advances in image-guided radiation therapy. J Clin Oncol 2007;25:938-946 [PMID 17350942]

No image available
Published
2012-03-10
How to Cite
SaifM., NgJ., ChangB., & RussoS. (2012). Is There a Role of Radiotherapy in the Management of Pancreatic Neuroendocrine Tumors (PNET)?. JOP. Journal of the Pancreas, 13(2), 174-176. https://doi.org/10.6092/1590-8577/690
Issue
Vol 13 No 2 (2012): March - p. 124-251
Section
Highlights from the “2012 ASCO Gastrointestinal Cancers Symposium”. San Francisco, CA, USA. January 19-21, 2012

Copyright (c) 2014 Muhammad Wasif Saif, John Ng, Bryan Chang, Suzanne Russo

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.